Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 12/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22825028 | 1.00 | TLR7 (0.43) | TLR7TLR8CDK1CDK5KCNH2 | |
| SCHEMBL21693478 | 0.92 | TLR7 (0.50) | TLR7TLR8KCNH2TRPM8 | |
| SCHEMBL19663389 | 0.85 | TLR7 (0.36) | TLR7TLR8KCNH2TRPM8P2RX3 | |
| SCHEMBL22805390 | 0.84 | TLR7 (0.43) | TLR7TLR8KCNH2TRPM8 | |
| SCHEMBL13195694 | 0.84 | TLR7 (0.54) | TLR7TLR8KCNH2 | |
| SCHEMBL20219473 | 0.84 | TLR7 (0.54) | TLR7TLR8KCNH2 | |
| SCHEMBL13195729 | 0.84 | TLR7 (0.54) | TLR7TLR8KCNH2 | |
| SCHEMBL20219616 | 0.84 | TLR7 (0.41) | TLR7TLR8CDK1CDK5KCNH2 | |
| SCHEMBL21693513 | 0.82 | TLR7 (0.42) | TLR7TLR8KCNH2TRPM8 | |
| SCHEMBL29017316 | 0.82 | TLR7 (0.42) | TLR7TLR8KCNH2TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3519406-B1 | PYRIMIDINE PRODRUGS FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2022-02-23 | — | — | EP | disclosed |
| US-20210214317-A1 | PYRIMIDINE PRODRUGS FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-07-15 | — | — | US | disclosed |
| US-10968184-B2 | Pyrimidine prodrugs for the treatment of viral infections and further diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2021-04-06 | — | — | US | disclosed |
| WO-2020255035-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIMIDINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| US-20200031779-A1 | PYRIMIDINE PRODRUGS FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2020-01-30 | — | — | US | disclosed |
| WO-2018060317-A1 | PYRIMIDINE PRODRUGS FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968184-B2 | Pyrimidine prodrugs for the treatment of viral infections and further diseases | TYMP, TYMS, PNP | TLR7 1077/4885TLR8 1650/4885CDK1 545/4885 |
| US-20200031779-A1 | PYRIMIDINE PRODRUGS FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | TYMP, TYMS, PNP | TLR7 1077/4885TLR8 1650/4885CDK1 545/4885 |
| US-20210214317-A1 | PYRIMIDINE PRODRUGS FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | TYMP, TYMS, PNP | TLR7 1077/4885TLR8 1650/4885CDK1 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.